A phase III trial in endometrial cancer in 6 sites in Russia and Estonia started.

7 February 2010

OCT started a phase III trial in endometrial cancer in 6 sites in Russia and Estonia. The study is to be launched also in Latvia, Lithuania and Czech Republic later in 2010.

OCT Vision

“OCT vision is to be recognized by pharmaceutical and biotech companies as a leading provider of clinical trials in Russia, Ukraine, Bulgaria, Belarus, Latvia, Lithuania, Estonia, Poland and Czech Republic. OCT is able to support any requirements that clients may have in the region, ranging from one-off advice to full-study implementation and execution. We are determined and decisive in expanding our activity at this rapidly growing market”— Dmitry Sharov, General Manager of OCT.